Senate Bill 2586, also known as House Bill 2246, amends Tennessee law to regulate stem cell therapies by adding a new section to Tennessee Code Annotated, Title 63, Chapter 6, Part 2. The bill defines important terms related to stem cell therapy and regenerative medicine, including "human cells, tissues, or cellular or tissue-based products," and outlines the conditions under which stem cell therapy can be performed. It prohibits the use of human cells or tissues derived from a fetus or embryo after an abortion and requires physicians to obtain patient consent and provide clear notices in advertisements. Furthermore, the bill allows physicians to perform unapproved stem cell therapies within their scope of practice, provided they source products from certified facilities and report any adverse events.

The legislation introduces new reporting requirements for physicians performing stem cell or regenerative medicine therapies, mandating that they report any adverse events to their licensing authority. The term "adverse event" encompasses various medical occurrences, including infections and unexpected clinical outcomes. Additionally, the bill empowers the board of medical examiners and the board of osteopathic examination to create rules for implementing these provisions, adhering to the Uniform Administrative Procedures Act. The act will take effect immediately for rule promulgation, while other provisions will become effective on July 1, 2026.